CORRIGENDUM

doi:10.1038/nature09759

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

Alexander D. Boiko, Olga V. Razorenova, Matt van de Rijn, Susan M. Swetter, Denise L. Johnson, Daphne P. Ly, Paris D. Butler, George P. Yang, Benzion Joshua, Michael J. Kaplan, Michael T. Longaker & Irving L. Weissman

Nature 466, 133-137 (2010)

In this Letter, Fig. 1b and Table 2 (summarizing experiments presented in Supplementary Figs 2-4 and 7-9) contained an error reflecting the total number of tumours formed, and the total number of injections with CD271⁺ cells isolated directly from patients (26 out of 37). The correct number is 25 out of 38. The total number of injections with CD271⁺ cells from xenografted tumours was incorrectly listed as 54 instead of 55, and the total number of injections with CD271⁻ should have been 44 rather than 43. In Table 1 (summarizing experiments with xenografted tumours P0, Pi) the total number of injections with CD271⁺ cells was incorrectly listed as 36 instead of 37, and the total number of injections with CD271⁻ cells should have been 26 rather than 25. In addition, in Fig. 3d the stacked bar column that shows the proportion of patients with different ranges of TYR positivity should indicate 19 instead of 17 for the 0%-positivity group, and 1 instead of 2 for the 90-98%-positivity group. Supplementary Table 3 also contained some errors. None of these alterations affect the significant differences or change the P value between CD271⁺ and CD271⁻ cells in their ability to initiate melanomas in RG mice, as discussed in the original report. The corrected Figs 1b, 3d and Tables 1 and 2 are shown below.

Table 1 | Summary of engraftments from xenografted tumours

, ,	
Cell surface phenotype (Xenografted samples P0, Pi)	Frequency of tumour formation
CD271 ⁺ CD271 ⁻	70% (26 of 37)* 19% (5 of 26)*

Table 2 | Comparative analysis of melanoma initiation

Tumour cell source	Frequency of tumour formation		
	CD271 ⁺	CD271 ⁻	
Patient samples Xenografted samples (P0, Pi, Ps)	66% (25 of 38) 71% (39 of 55)	7% (3 of 41)* 23% (10 of 44)*	

	Directly from patient samples					
Cell surface phenotype	CD271+	CD2	271-	hLin⁻		
Frequency o tumour form	% (25 of 38)	7% (3	of 41)	16% (5 of 30)		
	P <	0.0001				

Figure 1




Figure 3